Beacon Therapeutics | LinkedIn (original) (raw)
About us
Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD), an inherited retinal disease. Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. The Company is supported by funds from Syncona, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors.
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Alachua, Florida
Type
Privately Held
Founded
2023
Locations
Employees at Beacon Therapeutics
Updates
- We hope to see you at the European Society of Retina Specialists (EURETINA) Annual Meeting in Barcelona this week, where Paul Yang, MD, PhD, Chief, Paul H. Casey Ophthalmic Genetics Division, Casey Eye Institute (OHSU), is presenting 36-Month Interim Results from the Beacon Therapeutics’ Phase 1/2 HORIZON Study on September 19, 15:30 - 15:36 CEST. Thank you to Dr. Yang and to our team representing Beacon at EURETINA. Dr. Lance Baldo, Darin Curtiss, Ashley Simmons, Benjamin Rice, DO, Kathryn Burns, MHA, Amy Perniciaro and Doug Leonard. Please visit https://www.beacontx.com/ to see the presentation and learn more about the work we are doing at Beacon. #EURETINA24 #genetherapy #ophthalmology #retina
- We are very pleased to welcome another new executive team member to the Beacon team. Welcome Natasha Jarrett, who joins us as SVP Regulatory Affairs!
-
5,142 followers
1mo Edited
We are thrilled to share that Dr. Lance Baldo has joined Beacon as our new Chief Executive Officer! To learn more about our recent executive appointments, please click the link to the press release below. https://lnkd.in/e823cD5P - We are excited to welcome Tom Biancardi to the Beacon team as our Chief Financial Officer!
- Today, we announced the appointment of Lance Baldo, MD as CEO, effective August 12, 2024, and Thomas Biancardi as CFO, effective August 1, 2024. Current CEO, David Fellows was named non-Executive Chairman of the Board, effective January 2025. Lance and Tom bring a wealth of experience in biopharmaceuticals and ophthalmology and share our passion to develop potentially transformative ocular gene therapies for patients. We are thankful to Dave for his leadership and excited to welcome Lance and Tom to the Beacon team in August! To learn more about these executive appointments, please click the link to the press release below. https://lnkd.in/e823cD5P
Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer - Beacon Therapeutics https://www.beacontx.com - Thanks to Rajiv Anand, MD, FRCS, FASRS for presenting an encore of the 12-month interim safety and efficacy results of the Phase 2 SKYLINE trial in patients with X-linked retinitis pigmentosa (XLRP) at the ASRS – American Society of Retina Specialists 2024 Annual Scientific Meeting in Stockholm, Sweden. We look forward to sharing 24-month data from the Phase 2 SKYLINE trial later this year. To learn more about the work we are doing at Beacon to bring transformative ocular gene therapies to patients, please visit https://www.beacontx.com/ #ASRS2024 #XLRP
-
5,142 followers
3mo Edited
Beacon Therapeutics is pleased to announce that the first patient has been treated in our Phase 2/3 VISTA clinical trial for our lead asset, AGTC-501. This is an important clinical milestone for AGTC-501 and another promising step toward a potential treatment for patients with X-Linked Retinitis Pigmentosa (XLRP), a blinding orphan disease for which there is no available treatment. VISTA is a randomized, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 doses of AGTC-501 for the treatment of XLRP compared to an untreated control group. To learn more about our ongoing VISTA trial, click the link to the press release below.https://lnkd.in/ePRK4FJW
Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501 - Beacon Therapeutics https://www.beacontx.com